S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Generation Bio Stock Forecast, Price & News

-1.10 (-6.93%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
250,956 shs
Average Volume
192,330 shs
Market Capitalization
$841.13 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive GBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter.

Generation Bio logo

About Generation Bio

Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.


Generation Bio (NASDAQ:GBIO) Sets New 52-Week Low at $15.40
December 2, 2021 |  americanbankingnews.com
Generation Bio (NASDAQ:GBIO) Hits New 52-Week Low at $17.62
November 26, 2021 |  americanbankingnews.com
Generation Bio (NASDAQ:GBIO) Sets New 52-Week Low at $18.75
November 18, 2021 |  americanbankingnews.com
Generation Bio Presents Data Demonstrating First...
October 23, 2021 |  benzinga.com
Director Of Generation Bio Makes $2.0M Sale
September 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$7.16 per share


Net Income
$-80.52 million
Pretax Margin




Free Float
Market Cap
$841.13 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.53 out of 5 stars

Medical Sector

107th out of 1,390 stocks

Pharmaceutical Preparations Industry

45th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Generation Bio (NASDAQ:GBIO) Frequently Asked Questions

Is Generation Bio a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Generation Bio stock.
View analyst ratings for Generation Bio
or view top-rated stocks.

When is Generation Bio's next earnings date?

Generation Bio is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Generation Bio

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) posted its earnings results on Wednesday, November, 10th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.02.
View Generation Bio's earnings history

What price target have analysts set for GBIO?

4 brokerages have issued 12-month price targets for Generation Bio's shares. Their forecasts range from $39.00 to $50.00. On average, they anticipate Generation Bio's share price to reach $43.50 in the next year. This suggests a possible upside of 194.3% from the stock's current price.
View analysts' price targets for Generation Bio
or view top-rated stocks among Wall Street analysts.

Who are Generation Bio's key executives?

Generation Bio's management team includes the following people:
  • Dr. Cameron Geoffrey McDonough, Pres, CEO, Sec. & Director (Age 51, Pay $856.88k)
  • Dr. Matthew Norkunas M.B.A., M.D., Chief Financial Officer (Age 43, Pay $357.65k)
  • Dr. Tracy Zimmermann Ph.D., Chief Devel. Officer (Age 51, Pay $507.92k)
  • Dr. Robert Kotin Ph.D., Co-Founder & Advisor (Age 65)
  • Dr. Matthew Stanton Ph.D., Chief Scientific Officer (Age 48)
  • Dr. Jennifer Elliott Esq., J.D., Ph.D., Chief Legal Officer
  • Mr. Phillip Samayoa Ph.D., Sr. VP & Head of Corp. Devel.
  • Ms. Sara Den Besten, Chief People Officer
  • Dr. Douglas Kerr M.B.A., M.D., Ph.D., Chief Medical Officer (Age 54)
  • Ms. Antoinette Paone M.B.A., M.S., Sr. VP & Head of Regulatory Affairs and Quality

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Blockchain (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

When did Generation Bio IPO?

(GBIO) raised $126 million in an initial public offering on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Generation Bio's stock symbol?

Generation Bio trades on the NASDAQ under the ticker symbol "GBIO."

Who are Generation Bio's major shareholders?

Generation Bio's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.50%), Bellevue Group AG (4.35%), Carmignac Gestion (2.59%), Casdin Capital LLC (2.33%), Victory Capital Management Inc. (2.24%) and Geode Capital Management LLC (1.39%). Company insiders that own Generation Bio stock include Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, James E Flynn, Jason P Rhodes, Matthew Stanton and Venture Associates X L Atlas.
View institutional ownership trends for Generation Bio

Which institutional investors are selling Generation Bio stock?

GBIO stock was sold by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Ensign Peak Advisors Inc, Citigroup Inc., Marshall Wace LLP, Voloridge Investment Management LLC, Goldman Sachs Group Inc., Laurion Capital Management LP, and Rafferty Asset Management LLC. Company insiders that have sold Generation Bio company stock in the last year include Douglas Kerr, Evan Spiegel, Geoff Mcdonough, Jason P Rhodes, Matthew Stanton, and Venture Associates X L Atlas.
View insider buying and selling activity for Generation Bio
or view top insider-selling stocks.

Which institutional investors are buying Generation Bio stock?

GBIO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Victory Capital Management Inc., Dimensional Fund Advisors LP, SG Americas Securities LLC, Bank of New York Mellon Corp, Martingale Asset Management L P, and Cubist Systematic Strategies LLC. Company insiders that have bought Generation Bio stock in the last two years include Donald William Nicholson, and James E Flynn.
View insider buying and selling activity for Generation Bio
or or view top insider-buying stocks.

How do I buy shares of Generation Bio?

Shares of GBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Generation Bio's stock price today?

One share of GBIO stock can currently be purchased for approximately $14.78.

How much money does Generation Bio make?

Generation Bio has a market capitalization of $841.13 million. The company earns $-80.52 million in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does Generation Bio have?

Generation Bio employs 100 workers across the globe.

What is Generation Bio's official website?

The official website for Generation Bio is generationbio.com.

Where are Generation Bio's headquarters?

Generation Bio is headquartered at 301 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Generation Bio?

Generation Bio's mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-655-7500 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.